Webinars
April 9, 2025 | 12:00 - 12:30 PM ET
Two additional sessions will be offered: April 10 – 12:00 – 12:30 (UTC +8:00) – Asia/Shanghai April 10 – 12:00 – 12:30 CET – Europe/Berlin
Today’s launch environment is fraught with greater complexity, lack of standardization and executional inefficiency.
Join Trinity Life Sciences for a virtual “launch and learn” where Krista Perry—Partner & Head of Launch Excellence and Tarra Maeshima— Sr. Director of New Products & Strategy share how Trinity Launch Accelerator enables teams to overcome these typical launch barriers…
Sign Up Now
Webinars
White Paper & Webinar:
This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each on its commercial performance, therapeutic value and R&D investment.
2021 saw 40 unique drug and biologic approvals, of which ~33% (13/40) were Oncology, followed by ~18%…
Read Now
White Papers
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023).
This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior).
The needle is moving.
Complete the form below to access the full white paper
By submitting…
Read Now
Webinars
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, this webinar is a must-watch.
Join us for an informative webinar as our experts dive into Trinity Life Sciences’ latest white paper, the Trinity Annual Drug Index—an evaluation of commercial performance over three years of 58 novel drugs approved in 2020.
Hear from Blair Miller, Krista Perry, Hanson Koota and Smit Mahida from our Strategic Advisory practice as they discuss the impacts of COVID on the 2020 launch…
Watch Now
White Papers
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology…
Read Now
Webinars
Available On Demand
Join Trinity Life Sciences for a virtual lunch and learn where Krista Perry—Partner & Head of Launch Excellence, Curt Staab—Head of Client Development and Tarra Maeshima—Director of New Products & Strategy will demonstrate Trinity Launch Accelerator.
Launch project management office (PMO) teams and/or dedicated project manager (PM) resources are critical to enabling Launch Excellence-and the best support a PM can have is a single-source-of-truth launch planning and management tool that enables the integration necessary and takes work off everyone’s plate.…
Watch Now
Webinars
Available On Demand
Join Leslie Orne, President and CEO at Trinity Life Sciences, as she discusses how Trinity is helping life sciences companies launch in Europe at the Jefferies London Healthcare Conference.
Key Topics:
Trinity’s data-driven and insight-driven approach to support clients across their commercial journey.
Trinity’s expertise in helping clients plan market access, evaluate strategic options, develop a shortlist of partners and optimize their approach.
How Trinity’s local team in Europe can bring in-depth expertise, local language, regulatory experience and in-market experience…
Watch Now
White Papers
Trinity Life Sciences has been tracking and analyzing the challenges of commercialization and new product launches in the Biopharma industry for years (see our 2022 white paper, Empowering the Next-Generation Launch Model). One method we have leveraged to track the challenges in commercialization is new product launch performance, comparing first calendar year actual sales with consensus Wall Street analyst forecast estimates at time of launch for novel product (New Molecular Entities) launches within the U.S.
In this white paper, we…
Read Now
White Papers
This report, the fifth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2019, scoring each on its commercial performance, therapeutic value, and R&D investment. 2019 saw 53 unique drug and biologic approvals, of which the majority were neurology (~23%) followed by oncology (~21%). In this…
Read Now
Webinars
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, sales for innovative drugs in China are often only a fraction of those in the U.S. The complex and rapidly evolving market dynamics require companies…
Watch Now
